Budesonide + Placebo
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Perennial Allergic Rhinitis
Conditions
Perennial Allergic Rhinitis
Trial Timeline
Jan 1, 2000 → Apr 1, 2003
NCT ID
NCT00641212About Budesonide + Placebo
Budesonide + Placebo is a approved stage product being developed by AstraZeneca for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00641212. Target conditions include Perennial Allergic Rhinitis.
What happened to similar drugs?
6 of 20 similar drugs in Perennial Allergic Rhinitis were approved
Approved (6) Terminated (1) Active (14)
🔄ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
🔄Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01136382 | Phase 2 | Completed |
| NCT00642187 | Phase 3 | Completed |
| NCT00641979 | Phase 2 | Completed |
| NCT00641212 | Approved | Completed |
| NCT00641914 | Approved | Completed |
Competing Products
20 competing products in Perennial Allergic Rhinitis